Skip to main content
SpringerLink
Log in

Polymorphisms in GSTM1, CYP1A1, CYP2E1, and CYP2D6 are Associated with Susceptibility and Chemotherapy Response in Non-small-cell Lung Cancer Patients

  • Published:
Lung Aims and scope Submit manuscript

Abstract

Background

Studies of polymorphisms in CYP1A1, CYP2E1, CYP2D6, and GSTM1 and their relationship to lung cancer susceptibility and chemotherapy response have been reported, but the results are not consistent. In this study we selected four polymorphisms in these genes, several of which have previously been researched, and investigated their association with lung cancer susceptibility and chemotherapy response.

Methods

We genotyped the four polymorphisms in a cohort composed of 217 non-small-cell lung cancer (NSCLC) patients and 198 controls. Of these, 145 advanced NSCLC patients underwent chemotherapy and were monitored for 5 years.

Results

Significant differences in the GSTM1 polymorphism were observed between the case and control groups (P = 0.02). We observed a synergistic effect of smoking and GSTM1. Smokers with deficient-type GSTM1 had a 4.96-fold increased risk of developing lung cancer. Significant differences in GSTM1 and CYP1A1 polymorphisms were observed between the response and nonresponse groups (P = 0.004 and P = 0.026). Moreover, patients with deficient-type GSTM1 were superior responders to platinum drugs than those carrying wild-type GSTM1 (P = 0.014). In addition, patients carrying TT CYP1A1 responded better to nonplatinum drugs than those carrying TC and CC CYP1A1 (P = 0.01). Polymorphisms in the four enzymes had no effect on the overall survival of NSCLC patients.

Conclusions

Our findings support the hypothesis that a polymorphism in GSTM1 is associated with lung cancer susceptibility. Furthermore, polymorphisms in GSTM1 and CYP1A1 were associated with chemotherapy response. In particular, smokers carrying deficient-type GSTM1 were at a higher risk of developing lung cancer. Patients carrying deficient-type GSTM1 responded better to platinum drugs, while those with TT CYP1A1 were better responders to nonplatinum drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mo Z, Gao Y, Cao Y, Gao F, Jian L (2009) An updating meta-analysis of the GSTM1, GSTT1 and GSTP1 polymorphisms and prostate cancer: a HuGE review. Prostate 69:662–688

    Article  PubMed  CAS  Google Scholar 

  2. McCarty KM, Santella RM, Steck SE, Cleveland RJ, Ahn J, Ambrosone CB et al (2009) PAH-DNA adducts, cigarette smoking, GST polymorphisms, and breast cancer risk. Environ Health Perspect 117:552–558

    PubMed  CAS  Google Scholar 

  3. Mir O, Alexandre J, Tran A, Durand JP, Pons G, Treluyer JM (2009) Relationship between GSTP1 IIe (105) Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity. Ann Oncol 20:736–740

    Article  PubMed  CAS  Google Scholar 

  4. Sreeja L, Syamala V, Hariharan S, Syamala VS, Raveendran PB, Sivanandan CD et al (2008) Glutathinone S-transferases M1, T1 and P1 polymorphisms: susceptibility and outcome in lung cancer patients. J Exp Ther Oncol 7:73–85

    PubMed  CAS  Google Scholar 

  5. Idle JR (1991) Is environmental carcinogenesis modulated by host polymorphism? Mutat Res 247:259–266

    Article  PubMed  CAS  Google Scholar 

  6. Kim JW, Lee CG, Park YG, Kim KS, Kim IK, Sohn YW (2000) Combined analysis of germline polymorphisms of p53, GSTM1, GSTT1, CYP1A1, and CYP2E1: relationship to the incidence rate of cervical carcinoma. Cancer 88:2082–2091

    Article  PubMed  CAS  Google Scholar 

  7. Reszka E, Wasowicz W, Gromadzinska J (2006) Genetic polymorphism of xenobiotic metabolising enzymes, diet and cancer susceptibility. Br J Nutr 96:609–619

    PubMed  CAS  Google Scholar 

  8. Singh H, Sachan R, Devi S, Pandey SN, Mittal B (2008) Association of GSTM1, GSTT1, GSTM3 gene polymorphisms and susceptibility to cervical cancer in a North Indian population. Am J Obstet Gynecol 198:303e1–303e6

    Article  Google Scholar 

  9. Shi X, Zhou S, Wang Z, Zhou Z (2008) CYP1A1 and GSTM1 polymorphisms and lung cancer risk in Chinese population: a meta-analysis. Lung Cancer 59:155–163

    Article  PubMed  Google Scholar 

  10. Joseph T, Chacko P, Wesley R, Jayaprakash PG, James FV, Pillai MR (2006) Germline genetic polymorphisms of CYP1A1, GSTM1 GSTT1 genes in Indian cervical cancer: associations with tumor progression, age and human papillomavirus infection. Gynecol Oncol 101:411–417

    Article  PubMed  CAS  Google Scholar 

  11. Khedhaier A, Remadi S, Corbex M, Ahmed SB et al (2003) Glutathione S-transferases (GSTT1 and GSTM1) gene deletions in Tunisians: susceptibility and prognostic implications in breast carcinoma. Br J Cancer 89:1502–1507

    Article  PubMed  CAS  Google Scholar 

  12. Mellwain CC, Townsend DM, Tew KD (2006) Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene 25:1639–1648

    Article  Google Scholar 

  13. DeMichele A, Gimotty P, Botbyl J et al (2007) In response to “Drug metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort”. J Clin Oncol 25(35):5675–5677

    Article  PubMed  Google Scholar 

  14. Petros WP, Hopkins PJ, Spruill S et al (2005) Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. J Clin Oncol 23(25):6117–6125

    Article  PubMed  CAS  Google Scholar 

  15. Ambrosone CB, Sweeney C, Coles BF et al (2001) Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res 61(19):7130–7135

    PubMed  CAS  Google Scholar 

  16. Amirimani B, Ning B, Deitz AC, Weber BL, Kadlubar FF, Rebbeck TR (2003) Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ Mol Mutagen 42:299–305

    Article  PubMed  CAS  Google Scholar 

  17. Eichelbaum M, Ingelman-Sunberg M, Evans WE (2006) Pharmacogenomics and individualized drug therapy. Annu Rev Med 57:119–137

    Article  PubMed  CAS  Google Scholar 

  18. Beeghly A, Katsaros D, Chen H et al (2006) Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Gynecol Oncol 100(2):330–337

    Article  PubMed  CAS  Google Scholar 

  19. Tran A, Jullien V, Alexandre J et al (2006) Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 76(6):570–580

    Article  Google Scholar 

  20. Barragan E, Collado M, Cervera J et al (2007) The GST deletions and NQO1*2 polymorphisms confers interindividual variability of response to treatment in patients with acute myeloid leukemia. Leuk Res 31(7):947–953

    Article  PubMed  CAS  Google Scholar 

  21. Demichele A, Aplenc R, Botbyl J et al (2005) Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort. J Clin Oncol 23(24):5552–5553

    Article  PubMed  CAS  Google Scholar 

  22. Zhang Y, Yang L, Li R et al (2006) The effects of glutathione S-transferase (GSTT1 and GSTM1) genes polymorphisms on treatment efficacy and prognosis of acute myeloid leukemia. Zhonghua Nei Ke Za Zhi 45(3):213–216

    PubMed  CAS  Google Scholar 

  23. Tsvirenko SV, Tsaur GA (2006) Genetic polymorphism of glutathione-S-transferase M1 and T1 in children with acute lymphoblastic leukemia. Klin Lab Diagn (2):23–24, 33–34

  24. Medeiros R, Pereira D, Afonso N et al (2003) Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome. Int J Clin Oncol 8(3):156–161

    Article  PubMed  CAS  Google Scholar 

  25. Sarab LN, Bruno C, Pascal C et al (1999) Glutathione S-transferase N1 null genotype: lack of association with tumour characteristics and survival in advanced breast cancer. Breast Cancer Res 1(1):81–87

    Article  Google Scholar 

  26. Okcu MF, Selvan M, Wang LE et al (2004) Glutathione S-transferase polymorphisms and survival in primary malignant glioma. Clin Cancer Res 10(8):2618–2625

    Article  PubMed  CAS  Google Scholar 

  27. Maja K, Domian L, Geraldine M et al (2002) Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukaemia. Clin Cancer Res 8(3):802–810

    Google Scholar 

  28. Guo R, Chen L, Li L et al (2011) Association of GSTM1 null polymorphism with isosorbide-5-mononitrate cardiovascular response and involvement of CGRP in healthy Chinese male volunteers. Pharmacogenet Genomics 21(3):142–151

    Article  PubMed  CAS  Google Scholar 

  29. Ovsepian VA, EIu V, Sherstneva ES (2010) Cytochrome P4501A1, glutathione S-transferase M1 and T1 gene polymorphisms in chronic myeloid leukemia. Genetika 46(10):1360–1362

    PubMed  CAS  Google Scholar 

  30. Horgan AM, Yang B, Azad AK et al (2011) Pharmacogenetic and germline prognostic markers of lung cancer. J Thorac Oncol 6(2):296–304

    Article  PubMed  Google Scholar 

  31. Oliveira AL, Rodrigues FF, Santos RE et al (2010) GSTT1, GSTM1, and GSTP1 polymorphisms and chemotherapy response in locally advanced breast cancer. Genet Mol Res 9(2):1045–1053

    Article  PubMed  CAS  Google Scholar 

  32. Funke S, Timofeeva M, Risch A et al (2010) Genetic polymorphisms in GST genes and survival of colorectal cancer patients treated with chemotherapy. Pharmacogenomics 11(1):33–41

    Article  PubMed  CAS  Google Scholar 

  33. Baker SD, Verweij J, Cusatis GA et al (2009) Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther 85(2):155–163

    Article  PubMed  CAS  Google Scholar 

  34. Arruda VR, Lima CS, Grignoli CR et al (2001) Increased risk for acute myeloid leukaemia in individuals with glutathione S-transferase mu 1 (GSTM1) and theta 1 (GSTT1) gene defects. Eur J Haematol 66(6):383–388

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors acknowledge all members of the Medical Records Department for their contribution to data collection and organization at Beijing Chest Hospital. This project was supported by Beijing Talents Funded Projects (grant No. 2008ID0301300094).

Competing interests

The authors declare that they have no competing interests.

Author information

Authors and Affiliations

  1. Cell Biology Laboratory, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, No. 97 Ma Chang, Tongzhou District, Beijing, 101149, China

    WeiYing Li, WenTao Yue, LiNa Zhang, XiaoTing Zhao, Li Ma, XueHui Yang, ChunYan Zhang, Yue Wang & Meng Gu

Authors
  1. WeiYing Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. WenTao Yue
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. LiNa Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. XiaoTing Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Li Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. XueHui Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. ChunYan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yue Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Meng Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to WeiYing Li.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Li, W., Yue, W., Zhang, L. et al. Polymorphisms in GSTM1, CYP1A1, CYP2E1, and CYP2D6 are Associated with Susceptibility and Chemotherapy Response in Non-small-cell Lung Cancer Patients. Lung 190, 91–98 (2012). https://doi.org/10.1007/s00408-011-9338-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00408-011-9338-8

Keywords

Search

Navigation